MARKET

FHTX

FHTX

Foghorn Therapeutics Inc.
NASDAQ
6.28
+0.21
+3.46%
Closed 16:00 03/27 EDT
OPEN
6.15
PREV CLOSE
6.07
HIGH
6.31
LOW
6.02
VOLUME
55.16K
TURNOVER
0
52 WEEK HIGH
9.97
52 WEEK LOW
2.700
MARKET CAP
267.31M
P/E (TTM)
-2.6782
1D
5D
1M
3M
1Y
5Y
Foghorn to Host Conference Call and Webcast on Pipeline of Potential First-in-Class Medicines in Conjunction with the 2024 AACR Annual Meeting
Barchart · 2d ago
Weekly Report: what happened at FHTX last week (0318-0322)?
Weekly Report · 3d ago
Weekly Report: what happened at FHTX last week (0311-0315)?
Weekly Report · 03/18 11:38
Weekly Report: what happened at FHTX last week (0304-0308)?
Weekly Report · 03/11 11:34
Foghorn Therapeutics Inc. reports results for the quarter ended in December - Earnings Summary
Foghorn Therapeutics Inc. Reports results for the quarter ended in December. The company reported a quarterly adjusted loss of 57 cents per share. Revenue rose 37.9% to $5.77 million from the same quarter last year. The average analyst rating on the company's shares is "buy"
Reuters · 03/10 15:41
Foghorn Therapeutics Price Target Maintained With a $13.00/Share by Wedbush
Dow Jones · 03/08 15:19
Wedbush Reiterates Outperform on Foghorn Therapeutics, Maintains $13 Price Target
Benzinga · 03/08 15:08
Foghorn Therapeutics’ FHD-286: A Promising Contender in AML Treatment and Overcoming TKI Resistance
TipRanks · 03/08 11:28
More
About FHTX
Foghorn Therapeutics Inc. is a clinical-stage biotechnology company engaged in developing medicines that modulate gene expression through selectively targeting the chromatin regulatory system for therapeutic intervention in oncology. Its Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing to identify, validate and potentially drug targets within the system. The Company’s Traffic Control platform discovers and develops drugs in oncology and other therapeutic areas, including virology, autoimmune disease and neurology. The Company is developing FHD-286, a selective, allosteric ATPase inhibitor and which is evaluating two separate Phase I studies in metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia, and myelodysplastic syndrome. It is also developing FHD-909 a highly potent, allosteric and orally available small molecule.

Webull offers Foghorn Therapeutics Inc. stock information, including NASDAQ: FHTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FHTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading FHTX stock methods without spending real money on the virtual paper trading platform.